louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00430261: Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Official title: Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lung Cancer
Adenocarcinoma
Keywords: bronchoalveolar carcinoma
BAC
adenocarcinoma
lung cancer
oral
Stage IIIB and IV lung cancer
Any bronchoalveolar carcinoma (BAC)
Any adenocarcinoma in a never-smoker
Lead sponsor: Swedish Medical Center
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2007-02-01
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.

Detailed description: To participate in this study, patients must have disease that can be measured on a CT scan. Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown. Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.

Eligibility criteria: Inclusion Criteria:

* Bronchoalveolar carcinoma with disease measurable on CAT scan
* Any lung adenocarcinoma in a never-smoker (less than 100 cigarettes lifetime) with disease measurable on CAT scan
* Stage IIIB or IV

Exclusion Criteria:

* Uncontrolled hypertension
* Unstable brain metastases
* Pregnant/nursing women
* Uncontrolled thyroid disease

Primary outcomes:
measure: Progression-Free Survival
timeFrame: January 2009
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Swedish Cancer Institute
state: Washington
Study officials:
affiliation: Swedish Cancer Institute
name: Howard West, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02995161: Sun Protection Factor Assay (344/2016)
Official title: Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-12-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female.
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form).
* Signed and dated Informed Consent Form
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form.
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose).

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnosed by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma, diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
References:
Clinical trial NCT01877161: Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types
Official title: Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: To Healthy Volunteer
Virtual Lesions for Aphasia
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2013-06-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Repetitive transcranial magnetic stimulation induced virtual lesions for aphasia.

Detailed description: To evaluate the effect of navigated repetitive transcranial magnetic stimulation in subjects with aphasia after stroke.

Eligibility criteria: Inclusion Criteria:

* fluent in Korean
* older than 18 years old

Exclusion Criteria:

* younger than 18 years old
* psychotic or psychiatric problems
* pregnant
* contraindications to MRI/fMRI
* uncooperative
* metalic implants, pacemaker or cochlear implants
* cannot perform outcome measure-related task
* known seizure history

Primary outcomes:
measure: The Change of Reaction Time Between Before and After Stimulation in Each Session (MTG, STG, Sham)
timeFrame: change between before and after the TMS stimulation for each sessions (at session 1, session 2, session 3)
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Bundang-gu
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Nam-Jong Paik, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05548361: The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis
Official title: The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontitis
Chlorhexidine
Probiotic
Lead sponsor: Cukurova University
Sponsor class: OTHER
Collaborators: name: BioGaia AB
name: Sunstar
First posted: 2022-09-21
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is determining the additional effect of a 2-week home usage of chlorhexidine in periodontitis patients undergoing scaling and root planing supplemented with a dual-strain probiotic lozenge.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with generalized (\>30% of teeth affected) periodontitisstage III and IV periodontitis, grade B or C (C only with smoker modifier) = generalized chronic periodontitis including smokers
* A minimum of three natural teeth in each quadrant, excluding third molars
* Willing and able to give informed consent
* Not more than 50% of the patients in each group will be smokers.
* Smokers should smoke between 10 to 40 cigarettes a day

Exclusion Criteria:

* Patients with localized periodontitis or periodontitis stage I or II or grade A or grade C or grade C with diabetes modifier
* Patients with orthodontic appliances (removable or fixed)
* Pregnant or lactating woman
* Patients with a history of systemic diseases that may correlate with periodontal health, such as diabetesrheumatic fever, liver or kidney disease, and neurological deficiencies
* Patients taking medication which may affect the periodontium (bisphosphonates, phenytoin, cyclosporin, nifidepine, chronic use of non-steroidal anti-inflammatory drugs)
* Patient who had taken systemic antibiotics up to 3 months prior to treatment or medical conditions requiring prophylactic antibiotic coverage
* Participation in any other clinical study
* Tobacco chewing or sniffing

Primary outcomes:
measure: probing pocket depth
timeFrame: 6 months
Secondary outcomes:
measure: percentage of patients in low risk for disease progression
timeFrame: 6 months
measure: gingival recession
timeFrame: 6 months
measure: clinical attachment level
timeFrame: 6 months
measure: full mouth bleeding and plaque score
timeFrame: 6 months
measure: microbial outcomes
timeFrame: 6 months
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Cukurova university Faculty of Dentistry
Study officials:
References:
Clinical trial NCT06550661: Effects of Ba Duan Jin Training for Older People
Official title: Effects of Ba Duan Jin on Muscle Strength, Balance, Cardiorespiratory Endurance, Body Composition and Quality of Life of Older People
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Exercise
Old Age
Lead sponsor: Central Taiwan University of Science and Technology
Sponsor class: OTHER
First posted: 2024-08-13
Enrollment: 70
Sex: ALL
Minimum age (years): 60
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Baduanjin is one of the widely circulated fitness methods. The Ministry of Health, the Ministry of Education and the General Administration of Sports of China have vigorously promoted it as one of the contents of health and physical education classes, and promoted it as a health Qigong method throughout mainland China. It can be seen that Baduanjin's gentle and non-aggressive movements are suitable for physical training for people of all ages.


Eligibility criteria: Inclusion Criteria:

* (1) old person able to communicate and follow instructions, (2) stable and with sufficient physical strength: able to maintain at least one sitting position in a wheelchair or on the edge of a bed.

Exclusion Criteria:

* (1) Difficulty standing or walking and obvious musculoskeletal disease, (2) Diagnosed and recommended by a physician Those who are not suitable for sports activities, (3) serious diseases/unstable conditions, such as severe cardiopulmonary, liver and kidney diseases, severe malignant tumors, severe malnutrition, severe dementia, (4) more than 180 minutes of exercise per week in the past month time, (5) severe arrhythmia, (6) no intention to participate.

Primary outcomes:
measure: Chang in muscle strength from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in weight of muscle and fat from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in Activities of Daily Living from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in Instrumental activities of daily living from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in short form Berg balance scale from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in Gait analyses from wearable sensors from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in EQ5D from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
measure: Chang in WHOBREF from baseline to 12 weeks
timeFrame: Baseline and 12 weeks
Secondary outcomes:
measure: age, gender, married, religion, sleep, fall, disease status, education
timeFrame: Baseline
measure: height, weight
timeFrame: Baseline
measure: Clinical Dementia Rating
timeFrame: Baseline
measure: Chang in Cumulative Illness Rating Scale
timeFrame: Baseline
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Show Chwan Memorial Hospital
Study officials:
affiliation: Central Taiwan University of Science and Technology
name: Chiu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04412161: Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP
Official title: Retrospective Cohort Study-Analysis of LT Patients With HCC (Maximum Tumor Diameter > 6 cm).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Liver Transplant Disorder
Keywords: Hepatic malignancy
GGT
living donor
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2020-06-02
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Liver transplant patients with maximum tumor diameter greater than 6 cm of hepatocellular carcinoma

Brief summary: Retrospective data on 50 prospectively-collected HCC patients with beyond-Milan criteria with \>6cm tumors were analyzed. 5-year OS of 76.2% was found in patients with both AFP \<200 ng/ml and GGT \<104 IU/mL with tumors less than 10 cm diameter. Thus, GGT values add to AFP in patient prognosis.

Detailed description: Background:A retrospective analysis was performed of prospectively-collected transplant data on outcomes of patients with large size HCCs,to examine possible prognostically-useful factors.Methods:A total of 50 patients having tumors greater than 6cm maximum diameter were identified. Their survival and full clinical characteristics were examined, with respect to serum AFP and GGT levels.Results:Using ROC analysis, cutoff values of AFP 200 ng/ml and GGT 104 IU/ml were identified and used in this study. Significantly longer overall-survival and disease-free-survival were found for patients who had lower values of either parameter, compared with higher values.Even greater differences in survival were found when the 2 parameters were combined, with best survival (5-year OS of 76,2% versus 0%, p=0.002).The most consistent clinical correlates for these longer survivals were degree of tumor differentiation and absence of microscopic portal venous invasion.Two tumor size bands were identified,to search for the limits of this approach with larger tumors, namely 6-10 and \>10cm.Combination parameters in 6-10cm band reflected 5-year OS of 76,2% vs. 0%,in patients with low AFP plus low GGT vs. other groups.Beyond 10cm,no patients had low AFP plus low GGT.Conclusions:AFP and GGT,both singly and together, represent a simple prognostic identifier for patients with large size HCCs being treated by liver transplantation.

Eligibility criteria: Inclusion Criteria:

* Liver transplant patients with maximum tumor diameter greater than 6 cm of hepatocellular carcinoma

Exclusion Criteria:

* Early postoperative mortality (within 90 days)
* Advanced stage tumors (explant patology revealed that tumor continues in the surgical cite such as positive lymph node metastases, macroscopic portal vein trombosis, diaphragmatic invasion, etc)

Primary outcomes:
measure: overall and disease free survivals
timeFrame: five years follow up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01957761: Molecular Epidemiology of Clostridium Difficile Infections in Children
Official title: Molecular Epidemiologic Survey and Risk Factor Assessment of Clostridium Difficile Infections in Children: A Focus on Recurrent and Community-associated Infections
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Clostridium Difficile Infections
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2013-10-08
Enrollment: 132
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with Clostridium Difficile infection

Brief summary: Objectives:

1. Describe the molecular epidemiology of Clostridium Difficile infection in children in the Chicago area.
2. Determine the clinical spectrum and risk factors for Clostridium Difficile infection secondary to particular endemic strains in children.
3. Define the risk factors for recurrent and community-associated Clostridium Difficile infection in children.


Eligibility criteria: Inclusion Criteria:

* Clostridium Difficile infection

Exclusion Criteria:

* Age \< 1 year
* Age \> 18 years

Primary outcomes:
measure: Clostridium Difficile Infections Strain Type Based on Restriction Endonuclease Analysis
timeFrame: On day 1 of diagnosis of Clostridium difficile infection
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Ann & Robert H. Lurie Children's Hospital of Chicago
state: Illinois
Study officials:
References:
Clinical trial NCT06801561: EVALUATION of PREVENTIVE EFFECT of SEALANTS and LASER THERAPY on DENTAL CARIES and POSTERUPTIVE BREAKDOWN on MOLARS AFFECTED with MOLAR INCISOR HYPOMINERALISATION (RANDOMIZED CLINICAL TRIAL)
Official title: EVALUATION of PREVENTIVE EFFECT of SEALANTS and LASER THERAPY on DENTAL CARIES and POSTERUPTIVE BREAKDOWN on MOLARS AFFECTED with MOLAR INCISOR HYPOMINERALISATION (RANDOMIZED CLINICAL TRIAL)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Molar Incisor Hypomineralization
Keywords: Molar Incisor Hypomineralisation
laser
sealant
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-01-30
Enrollment: 134
Sex: ALL
Minimum age (years): 6
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Molar Incisor Hypomineralisation (MIH) is a qualitative defect of enamel that shows asymmetrical involvement of one to four permanent first molars (PFM) with or without incisor teeth involvement. MIH molars are prone to post-eruptive breakdown (PEB) and to the development of atypical caries lesions.

Aim of the study: To evaluate and compare the preventive effect of glass ionomer sealant and laser therapy (LT) against dental caries and PEB on molars affected by molar incisor hypomineralisation (MIH) Materials and Method: This study is a two-arm, parallel group, randomized clinical trial. A sample of children (n=134) with an age range of 6-9 years old, having a first permanent molar erupted with MIH without PEB or carious lesion, will be selected from the outpatient clinic of Pediatric Dentistry and Public Health Department, Faculty of Dentistry, Alexandria University after securing necessary consents. All selected 134 first permanent molars will be randomly and equally allocated into two groups. Group 1(n=67): LT and Group 2 (n=67): Glass ionomer sealant (Fuji triage). Dental caries, PEB, retention of sealant and child-self-reported discomfort will be clinically evaluated after 6, 12 and 18months. Associations between dental caries and PEB with independent variables will be evaluated using logistic regression analysis (p \< 0.05).


Eligibility criteria: Inclusion Criteria:

* 6-9 years old children (29)
* One tooth with MIH with no PEB according to evaluation criteria proposed by Ghanim (2017) (APPENDIX I) (30) and ICDAS scores 0, 1 and 2 (APPENDIX II) (31)
* Good overall health (ASA I) (APPENDIX III) (32)

Exclusion Criteria:

* First permanent molars with active carious lesions with ICDAS scores 5 and 6 (Appendix II) or defective restorations (31)
* Sufficient dentin loss that requires restorative therapy
* Any clinical signs of failure (abscess, fistula)

Primary outcomes:
measure: Post-eruptive breakdown / dental caries
timeFrame: 21 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Alexandria University
Study officials:
References:
Clinical trial NCT05146661: NEURESCUE Device as an Adjunct to Cardiac Arrest
Official title: An In-hospital Feasibility Study of the NEURESCUE Device as an Adjunct to Cardiac Arrest
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Arrest
Cardiopulmonary Arrest
Cardiovascular Diseases
Lead sponsor: neurescue
Sponsor class: INDUSTRY
First posted: 2021-12-07
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The NEURESCUE device is the first intelligent balloon catheter for aortic occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.

The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.

The objective of the study is to investigate the safety and performance of the NEURESCUE device as an adjunct to Advanced Life Support (ALS) in adults with cardiac arrest.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 and ≤79 years
2. Witnessed cardiac arrest
3. CPR initiated within 7 min of presumed arrest
4. Cardiac arrest not responding to standard ALS
5. Total CPR time ≤ 40 min at the time of screening for enrollment

Exclusion Criteria:

1. Traumatic cardiac arrest
2. Known pregnancy
3. Known terminal disease
4. Known Do-Not-Resuscitate (DNR) order
5. Subjects whose femoral arterial access site cannot accommodate an 8 Fr introducer sheath
6. Subjects currently on mechanical circulatory support

Primary outcomes:
measure: Successful balloon inflation within 10 minutes from first vessel puncture
timeFrame: Assessed up to 10 min
Secondary outcomes:
measure: Change in central blood pressure
timeFrame: At the initiation of balloon inflation compared to two minutes after finalizing balloon inflation
measure: Total cardiopulmonary resuscitation (CPR) time at the screening for enrollment
timeFrame: From initiation of cardiopulmonary resuscitation (CPR) to screening for enrollment
measure: Total ALS time at initiation of the investigational procedure
timeFrame: From initiation of ALS to initiation of the investigational procedure
measure: Time from first vessel puncture to successful sheath insertion
timeFrame: From first needle stick to successful sheath insertion
measure: Rate of occlusion success
timeFrame: Assessed up to 1 hour
measure: Return of spontaneous circulation (ROSC)
timeFrame: Assessed up to 1 hour
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité - Universitätsklinikum Berlin
city: Heidelberg
country: Germany
facility: Universitätsklinikum Heidelberg
Study officials:
affiliation: University Hospital Heidelberg
name: Michael Preusch, M.D.
role: PRINCIPAL_INVESTIGATOR
References: